Key result
Platelet function testing shows no benefit for guiding antiplatelet therapy in PCI patients.
Why the study?
There is interindividual variability in response to antiplatelet medications after PCI, and the clinical benefit of platelet function testing to guide treatment adjustments remains uncertain.
Does platelet function testing to guide antiplatelet treatment adjustments improve clinical outcomes in patients undergoing PCI?
Does platelet function testing to guide antiplatelet treatment adjustments improve clinical outcomes in patients undergoing PCI?
Answers are grounded in this paper and cite their sources.
Although platelet function testing has prognostic value for predicting thrombotic and bleeding risks, current randomized trials do not support routine antiplatelet treatment adjustments based on these tests.
Guidelines provide a Class IA recommendation for the use of dual antiplatelet therapy in patients undergoing percutaneous coronary intervention (PCI). However, there is interindividual variability in the pharmacodynamic response to antiplatelet medications. Some patients present with a status of high on-treatment platelet reactivity (HPR) during platelet function testing after standard doses of antiplatelet drugs, reflecting a failure to achieve adequate platelet inhibition. As an example, patients with HPR on clopidogrel are at increased risk for thrombotic events, particularly for stent thrombosis and myocardial infarction, but cardiovascular mortality is also elevated. On the contrary, low on-treatment platelet reactivity or an enhanced response to antiplatelet medications has been linked to a higher risk for bleeding. Although both thrombotic and bleeding events are multifactorial in origin, there is supportive evidence for the prognostic value of platelet function testing for risk prediction of both sides of the coin. However, although small studies have provided evidence that treatment adjustments based on platelet function testing results may improve clinical outcomes, the available randomized controlled trials showed no benefit of modifying antiplatelet treatment based on platelet function testing. This review presents the current evidence regarding platelet function testing in patients undergoing PCI. The prognostic value of platelet function testing regarding ischemic and bleeding events is highlighted. Furthermore, the value of platelet function testing for guiding treatment and possible explanations for the so-far negative trial results are presented. The possible future role of platelet function testing for individualized antiplatelet treatment regimens in high-risk patients will be also discussed.
No takes yet. Share an insight, caveat, or question.
Aradi et al. (2016) conducted a review in Patients undergoing percutaneous coronary intervention (PCI) on antiplatelet medications. Platelet function testing was evaluated. Platelet function testing has prognostic value for ischemic and bleeding events in PCI patients, but available randomized trials show no benefit of modifying antiplatelet treatment based on results.
Synapse has enriched 10 related papers. Consider them for comparative context: